Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Offering people a choice for colorectal cancer screening

A study in the latest issue of Gut examines the effect of offering people a choice for colorectal cancer screening.

News image

Dr Carlo Senore and colleagues from Italy assessed the population coverage and diagnostic yield of offering an immunochemical fecal occult blood test to non-responders to a flexible sigmoidoscopy invitation.

A cohort study conducted in a population-based colorectal cancer screening program.

In this program, eligible men and women aged 58 or 60 are invited, with a personal letter signed by their general practitioner, to undergo an flexible sigmoidoscopy.

Bowel preparation is limited to a single enema self-administered at home.
 
Subjects in whom one distal polyp more than 5 mm or at least one adenoma is detected at flexible sigmoidoscopy are referred for colonoscopy.

19% underwent an immunochemical fecal occult blood test
Gut

The team reported that people who do not respond to the invitation to undergo an flexible sigmoidoscopy are invited to have an immunochemical fecal occult blood test.

Attendance rate and neoplasia yield were analyzed in 4 consecutive birth cohorts.

The research team found that overall participation rate for the flexible sigmoidoscopy invitation was 39% in Verona, and 30% in Turin.

Of the eligible non-responders to the flexible sigmoidoscopy invitation, 19% underwent an immunochemical fecal occult blood test.

As a result, the team reported that the proportion of people undergoing screening by flexible sigmoidoscopy or immunochemical fecal occult blood test was 55% in Verona, and 39% in Turin, with no gender differences in either center.

Immunochemical fecal occult blood test detected 8% of all advanced adenomas, and 20% of all colorectal cancers diagnosed at screening.

Dr Senore's team concludes, "A strategy involving the sequential offer of flexible sigmoidoscopy, and immunochemical fecal occult blood test is a feasible and efficient approach."

"Immunochemical fecal occult blood test in people not attending for flexible sigmoidoscopy increases screening uptake and detection of advanced adenomas and colorectal cancers."

Gut 2013; 62: 735-740 
10 April 2013

Go to top of page Email this page Email this page to a colleague

 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Breath as a marker for IBS
 10 June 2016 
Rectal cancer surgery checklist
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis
 30 May 2016 
Challenges for direct-acting antivirals in Hep C
 30 May 2016 
Endoscopic indices for disease activity in ulcerative colitis
 30 May 2016 
Colonoscopy reimbursement reduction in practice

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us